# 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

> **NCT01038635** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 94 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** 5-Azacytidine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01038635
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01038635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01038635, "5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01038635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*